• metastatic/advanced - breast cancer (mBC) 1
• cervical cancer (CC)
• classical Hodgkin lymphoma (cHL)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• anti-PD-(L)1
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone

• versus all
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone
• vs others immune checkpoint inhibitors
• vs brentuximab vedotin
• vs non active control
• vs no additional treatment

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)